You are here

Scheduling delegate's final decisions, July 2016

Scheduling medicines and poisons

27 October 2016

Book pagination

Summary of delegate's final decisions

Part B – Final decisions on matters not referred to an expert advisory committee

5. New Chemical Entities - medicines for human therapeutic use

Summary of delegate's final decisions
Substance Final decision
Ocrelizumab

Schedule 4 - New Entry

OCRELIZUMAB.

Implementation date: 1 February 2017

Eluxadoline

Schedule 4 - New Entry

ELUXADOLINE.

Implementation date: 1 February 2017

Book pagination